Study of Dasatinib in Combination With Everolimus for Children and Young Adults With Gliomas Harboring Platelet-Derived Growth Factor Receptor (PDGFR) Alterations

NCT03352427 · clinicaltrials.gov ↗

PHASE2

Phase

TERMINATED

Status

3

Enrollment

OTHER

Sponsor class

Stopped Low accrual

Conditions

Glioma
High Grade Glioma
Pontine Tumors

Interventions

DRUG: Dasatinib
DRUG: Everolimus

Sponsor

University of Michigan Rogel Cancer Center